Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kane Biotech","sponsor":"University of Maryland School of Medicine\u2019s Institute of Human Virology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, Expanding Its DispersinB\u00ae Applications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech Successfully Completes Safety and Biocompatibility Studies for DispersinB Wound Gel in Preparation for Human Clinical Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Marc Edwards","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Announces Update on Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB\u00ae Hydrogel from the United States Department of Defense","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Salud Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Announces First Distribution Agreement for its Coactiv+\u2122 Antimicrobial Hydrogel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"ProgenaCare Global","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.5 million","newsHeadline":"Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+\u2122 Antimicrobial Wound Gel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech Announces FDA 510(k) Clearance for its coactiv+\u2122 Antimicrobial Wound Gel","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve\u2122 Antimicrobial Wound Gel at Advanced Wound Care Fall Forum","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Kane Biotech

    Menu

    Kane Biotech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Kane Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum

              Details:

              revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.

              Lead Product(s): Edetate Calcium Disodium,Citric Acid

              Therapeutic Area: Podiatry Product Name: Revye

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel

              Details:

              coactiv+ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.

              Lead Product(s): EDTA acid,Citric Acid

              Therapeutic Area: Podiatry Product Name: coactiv+

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+™ Antimicrobial Wound Gel

              Details:

              Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfactant.

              Lead Product(s): Edetate Calcium Disodium,Sodium Citrate

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: ProgenaCare Global

              Deal Size: Undisclosed Upfront Cash: $0.5 million

              Deal Type: Agreement April 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Announces First Distribution Agreement for its Coactiv+™ Antimicrobial Hydrogel

              Details:

              The coactiv+™ (disodium EDTA) Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.

              Lead Product(s): Edetate Calcium Disodium,Sodium Citrate

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Salud Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States Department of Defense

              Details:

              The funding supplements the clinical development of Kane’s DispersinB Hydrogel to treat biofilm-mediated antimicrobial resistance in non-healing chronic wounds. The DispersinB is a hydrogel wound dressing containing the enzyme DispersinB and the gelling agent Pluronic® F-127.

              Lead Product(s): DispersinB

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: DispersinB Hydrogel

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: U.S. Department of Defense

              Deal Size: $2.7 million Upfront Cash: Undisclosed

              Deal Type: Funding October 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Announces Update on Private Placement

              Details:

              The funding will be used primarily for product development including DispersinB and general working capital. The Company has a portfolio of biotechnologies, intellectual property (81 patents) and products developed by the Company's own biofilm research expertise.

              Lead Product(s): DispersinB

              Therapeutic Area: Dermatology Product Name: DispersinB

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Marc Edwards

              Deal Size: $1.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement May 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Successfully Completes Safety and Biocompatibility Studies for DispersinB Wound Gel in Preparation for Human Clinical Trials

              Details:

              DispersinB® wound gel underwent an extensive pre-clinical testing regimen showing it to be safe, non-toxic and non-irritating, in addition, DispersinB® significantly accelerated healing of both infected and non-infected dermal wound compared to control.

              Lead Product(s): DispersinB

              Therapeutic Area: Dermatology Product Name: DispersinB

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kane Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, Expanding Its DispersinB® Applications

              Details:

              DispersinB®, has properties that bacteriophages do not have which include superior application as a preventative therapeutic, broader spectrum of activity, and a much easier regulatory (FDA) path.

              Lead Product(s): DispersinB

              Therapeutic Area: Infections and Infectious Diseases Product Name: DispersinB

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: University of Maryland School of Medicine’s Institute of Human Virology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY